Suppr超能文献

基于吡咯的肝选择性配体作为HMG-CoA还原酶强效抑制剂的发现。

Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.

作者信息

Bratton Larry D, Auerbach Bruce, Choi Chulho, Dillon Lisa, Hanselman Jeffrey C, Larsen Scott D, Lu Gina, Olsen Karl, Pfefferkorn Jeffrey A, Robertson Andrew, Sekerke Catherine, Trivedi Bharat K, Unangst Paul C

机构信息

Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI 48105, USA.

出版信息

Bioorg Med Chem. 2007 Aug 15;15(16):5576-89. doi: 10.1016/j.bmc.2007.05.031. Epub 2007 May 17.

Abstract

In an effort to identify hepatoselective inhibitors of HMG-CoA reductase, two series of pyrroles were synthesized and evaluated. Efforts were made to modify (3R,5R)-7-[3-(4-fluorophenyl)-1-isopropyl-4-phenyl-5-phenylcarbamoyl-1H-pyrrol-2-yl]-3,5-dihydroxy-heptanoic acid sodium salt 30 in order to reduce its lipophilicity and therefore increase hepatoselectivity. Two strategies that were explored were replacement of the lipophilic 3-phenyl substituent with either a polar function (pyridyl series) or with lower alkyl substituents (lower alkyl series) and attachment of additional polar moieties at the 2-position of the pyrrole ring. One compound was identified to be both highly hepatoselective and active in vivo. We report the discovery, synthesis, and optimization of substituted pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase for reducing low density lipoprotein cholesterol (LDL-c) in the treatment of hypercholesterolemia.

摘要

为了鉴定HMG-CoA还原酶的肝选择性抑制剂,合成并评估了两个系列的吡咯。人们努力对(3R,5R)-7-[3-(4-氟苯基)-1-异丙基-4-苯基-5-苯基氨基甲酰基-1H-吡咯-2-基]-3,5-二羟基庚酸钠盐30进行修饰,以降低其亲脂性,从而提高肝选择性。探索的两种策略是用极性官能团(吡啶基系列)或低级烷基取代基(低级烷基系列)取代亲脂性的3-苯基取代基,并在吡咯环的2-位连接额外的极性部分。鉴定出一种化合物在体内具有高度肝选择性且具有活性。我们报告了基于取代吡咯的肝选择性配体作为HMG-CoA还原酶的有效抑制剂的发现、合成和优化,用于在高胆固醇血症治疗中降低低密度脂蛋白胆固醇(LDL-c)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验